

ODM&W/ODMA/MANAGR;238747;1
DEB/BWM/ctmra
07/06/01

PATENT APPLICATION
DOCKET NO.:3028.1000-000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Guy A. Rouleau and Bernard Brais

Application No.: 09/390,211 Group Art Unit: 1632

Filed: June 8, 2000 Examiner:

Title: SHORT GCG EXPANSIONS IN THE PAB II GENE FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY AND DIAGNOSTIC THEREOF

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231

on July 9, 2001 *Christina M. McSwaney*
 Date Signature

Christina M. McSwaney
 Typed or printed name of person signing certificate

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir;

This Information Disclosure Statement is submitted:

[] under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

[] under 37 CFR 1.97(c) together with either:

[] a Statement under 37 CFR 1.97(c), as checked below, or

[] a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with:
 Statement under 37 CFR 1.97(c), as checked below, and

a \$180.00 fee under 37 CFR 1.17(p), or

under 37 CFR 1.97(i):
I request you note that the IDS and cited reference(s) be placed in the application filewrapper.

09/590,211

-2-

Statement Under 37 CFR 1.97(c)

Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Enclosed herewith is form PTO-1449:

Copies of the cited references are enclosed.

Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]

The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:

the explanation provided on the attached sheet.

the explanation provided in the Specification.

submission of the enclosed International Search Report.

the enclosed English language abstract.

Applicant requests that the following pending applications be considered:

Inventor(s)
Init. & S.

U.S. Patent Application No. [], Publication No. [], Publication Date [],
by [inventor(s)], filed [], Docket No.: []

U.S. Patent Application No. [], Publication No. [], Publication Date [],
by [inventor(s)], filed [], Docket No.: []

U.S. Patent Application No. [], Publication No. [], Publication Date [],
by [inventor(s)], filed [], Docket No.: []

Examiner

Date

09/590,211

-3-

A copy of each above-cited application, including the current claims, is enclosed.

A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.

Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

David E. Brock RN 22592
By Elizabeth W. Mata
Elizabeth W. Mata
Registration No.: 38,236
Telephone: (781) 861-6240
Facsimile: (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: 7/9/01

DOC ID NO.: 3028.1000-000

PTO-1449 (07-97)

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

July 6, 2001

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
3028.1000-000APPLICATION NO.
09/590,211APPLICANT
Guy A. Rouleau, et al.FILING DATE
June 8, 2000GROUP
1632

U.S. PATENT DOCUMENTS

EXAM- INER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
AM						
AN						
AO						
AP						
AQ						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AX3	TOMÉ M.S., et al., "Nuclear Inclusions in Oculopharyngeal Dystrophy", <i>Acta Neuropathologica</i> , 49:85-87 (1980).
AX3	LaFrénieré R.G., et al., "Unstable insertion in the 5' flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1", <i>Nature Genetics</i> , 15:298-302 (March 1997).
AX3	Ronanous J.M., et al., "Towards a Transcriptional Map of the q21-q22 Region of Chromosome 7", <i>Plenum Press</i> , pp:65-79 (1994).

EXAMINER

DATE CONSIDERED